BSEAdvik Laboratories LtdHighNeutral
Announced Thu, 13 Aug, 2026 · 14:42 IST
MPS Pharmaa Q1 FY27 loss widens; zero revenue, auditor flags qualifications
Qualified audit opinionEmphasis of matterNet loss reportedResults View source PDFExplain this filing
Price reaction
Awaiting price reaction for this filing.
AI summary
MPS Pharmaa (formerly Advik Laboratories) reported Q1 FY27 standalone loss of Rs 23.80 Lacs versus Rs 22.01 Lacs loss year ago. Net sales were NIL; only Rs 3.56 Lacs other income. EPS minus Rs 0.12. Auditor issued qualified conclusion over Rs 53.80 Lacs missing share certificates and Rs 2.12 Crore stalled capital work. Emphasis of matter noted on zero revenue. Operations halted pending FDA license renewal. BSE trading suspended over unpaid listing fees since FY22.
Likely market impact
Continued losses with zero revenue, auditor qualifications and suspended trading signal serious operational and compliance distress for shareholders.